Potassium Supplements Monograph for Professionals - Drugs.com

Skip to main content
Print

# Potassium Supplements

Brand names: Effer-K, Kaon-Cl, Kay Ciel, K-Lor, Klor-Con, ... show all 9 brands Klor-Con/EF, Klotrix, K-Tab, Micro-K
Drug class: Replacement Preparations
CAS number: 127-08-2

## Introduction

A source of potassium, an essential nutrient cation.

## Uses for Potassium Supplements

### Hypokalemia

Treatment or prevention of hypokalemia (potassium deficiency) in patients in whom dietary measures are inadequate.

Conditions that may indicate or result in potassium deficiency include vomiting, diarrhea, drainage of GI fluids, hyperadrenalism, malnutrition, debilitation, prolonged negative nitrogen balance, prolonged parenteral alimentation without addition of potassium, dialysis, metabolic alkalosis, metabolic or diabetic acidosis, GI tract abnormalities that result in poor absorption, certain renal diseases, and familial periodic paralysis characterized by hypokalemia.

Potassium should be included in long-term electrolyte replacement regimens and has been recommended for routine prophylactic administration following surgery after adequate urine flow has been established.

Potassium replacement may be indicated in patients receiving certain drugs that may sometimes cause potassium depletion (e.g., thiazide diuretics, carbonic anhydrase inhibitors, loop diuretics, some corticosteroids, corticotropin, aminosalicylic acid, amphotericin B). Although ingestion of potassium-rich foods and/or use of potassium-containing salt substitutes may prevent potassium depletion in patients receiving potassium-depleting drugs, judicious prophylactic administration of potassium may be advisable in selected patients during prolonged diuretic or corticosteroid therapy, especially if they are digitalized.

Potassium chloride usually is the salt of choice in the treatment of potassium depletion, since the chloride ion is required to correct hypochloremia which frequently accompanies potassium deficiency and since the citrate, bicarbonate, gluconate, or another alkalinizing salt of potassium may cause hypochloremia, particularly when used in conjunction with chloride-restricted diets.

Alkalinizing potassium salts (acetate, bicarbonate, citrate, gluconate) should be used for treatment of hypokalemia in patients with metabolic acidosis (e.g., renal tubular acidosis).

Potassium also is available as the potassium phosphate salt; however, potassium phosphate usually is used to replace phosphate losses or to correct coexisting hypokalemia and hypophosphatemia.

### Hypertension

Inadequate dietary intake of potassium plays an important role in the development of hypertension, and high dietary intake of potassium (including use of potassium supplements) may protect against the development of high blood pressure and improve blood pressure control in patients with hypertension.

Most experts recommend enhanced intake of potassium (3.5–5 g daily) in hypertensive patients as part of lifestyle modifications unless contraindicated by chronic kidney disease (CKD) or use of drugs that reduce potassium excretion. (See Cautions: Precautions and Contraindications.) Increased potassium intake is recommended particularly in those unable to adequately reduce their sodium intake.

Adequate intake of potassium should be considered as a means of preventing the development of hypertension. Food sources high in potassium such as fruits and vegetables are preferred over potassium supplements.

### Arrhythmias

Potassium salts may be used cautiously to abolish arrhythmias of cardiac glycoside toxicity precipitated by a loss of potassium.

Elevation of plasma potassium concentrations by 0.5–1.5 mEq/L or to the ULN may be useful in the management of tachyarrhythmias following cardiac surgery, but this strategy should not be used in patients with atrioventricular block since potassium may further impair nodal conduction.

### Thallium Toxicity

IV potassium supplements, usually potassium chloride, have been used in the management of thallium poisoning† [off-label] to enhance diuresis and mobilize thallium from tissues; such treatment is limited by the amount of thallium that can be released into the blood without worsening cerebral symptoms.

## Potassium Supplements Dosage and Administration

### Administration

Administer orally or by slow IV infusion. Potassium-containing injections (usually potassium chloride), have been administered by hypodermoclysis† [off-label] (into subcutaneous tissues).

Potassium acetate, bicarbonate, chloride, citrate, and gluconate can be administered orally. Potassium acetate and chloride can be administered IV.

Whenever possible, potassium supplements should be given orally since the relatively slow absorption from the GI tract prevents sudden, large increases in plasma potassium concentrations. Replace IV potassium therapy with oral supplements and/or ingestion of potassium-rich foods as soon as possible.

#### Oral Administration

Oral potassium supplements should preferably be administered with or after meals with a full glass of water or fruit juice to minimize the possibility of GI irritation and a saline cathartic effect.

Usually administered orally in 1–4 doses daily. Daily dosage >20 mEq should be divided into several doses and should not be given as a single dose.

Powders or tablets for oral solution should be dissolved and/or diluted and administered according to the manufacturers’ directions.

Extended-release potassium chloride preparations should be reserved for use in patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for those in whom there is a problem of compliance with these latter dosage forms.

#### IV Infusion

Close monitoring of ECG and plasma potassium concentrations is essential during IV administration of potassium, especially when the rate of administration is >20 mEq/hour. (See Hyperkalemia under Cautions.)

Potassium IV solutions should generally be administered only in patients with adequate urine flow (e.g., administer to postoperative patients only after adequate urine flow established).

In dehydrated patients, 1 liter of potassium-free fluid should be administered prior to initiating potassium therapy.

Local vascular intolerance may limit the ability to administer concentrated solutions; administer via large, high-flow vein (e.g., femoral vein) or administer less concentrated solutions in divided doses via 2 veins simultaneously. Avoid administration of concentrated potassium solutions via subclavian, jugular, or right atrial catheter; local potassium concentrations achieved in the heart may be high and potentially cardiotoxic.

Potassium chloride injection in plastic containers should not be used in series connections with other plastic containers, since such use could result in air embolism from residual air being drawn from the primary container before administration of fluid from the secondary container is complete.

Hyperkalemia has been reported when concentrated potassium chloride solutions were added to IV infusions from a hanging flexible plastic container, apparently as a result of pooling of the concentrated potassium solution at the base of the container and infusion of undiluted solution. Squeezing the container does not facilitate mixing but tends to pump the concentrated solution into the infusion chamber. Such solutions must be carefully mixed by inverting the plastic container during the addition of potassium solutions with subsequent agitation and/or kneading to prevent pooling.

##### Dilution

For solution and drug compatibility information, see Compatibility under Stability.

Potassium acetate and potassium chloride are available as concentrates that must be diluted prior to IV administration.

Generally, potassium concentrations in IV fluids should not exceed 40 mEq/L. However, higher potassium concentrations (e.g., 60–80 mEq/L) occasionally may be needed initially for management of severe hypokalemia and associated cardiac arrhythmias, diabetic ketoacidosis or diuretic phase of acute renal failure.

##### Rate of Administration

Must be administered by slow IV infusion. Generally, rate of administration should not exceed 20 mEq/hour.

More rapid administration occasionally may be necessary for management of severe hypokalemia and associated cardiac arrhythmias or diabetic ketoacidosis or diuretic phase of acute renal failure.

#### Hypodermoclysis

If administered by hypodermoclysis† [off-label], potassium concentrations should not exceed 10 mEq/L to avoid local pain.

### Dosage

Dosage of potassium supplements usually expressed as mEq of potassium.

Normal adult daily potassium requirement and usual dietary intake of potassium is 40–80 mEq; infants may require 2–3 mEq/kg or 40 mEq/m2 daily.

Dosage must be carefully individualized according to the patient’s requirements and response.

To avoid serious hyperkalemia, replacement of potassium deficits must be undertaken gradually, usually over a 3- to 7-day period depending on the severity of the deficit.

Potassium replacement requirements can be estimated only by clinical condition and response, ECG monitoring, and/or plasma potassium determinations.

Dosage Equivalents of Oral Potassium Salts
40 mEq of potassium is provided by approximately:
3.9 g of potassium acetate
4.0 g of potassium bicarbonate
3.0 g of potassium chloride
4.3 g of potassium citrate
9.4 g of potassium gluconate

#### Pediatric Patients

##### Hypokalemia† [off-label]

###### Prevention or Treatment† [off-label]

Oral

If used in pediatric patients†, do not exceed 3 mEq/kg daily in young children.

#### Adults

##### Hypokalemia

###### Prevention

Oral

Average dosage approximately 20 mEq daily. Usually should not exceed 200 mEq daily.

###### Treatment

Oral

Usual dosage is 40–100 mEq or more daily. Usually should not exceed 200 mEq daily.

### Prescribing Limits

#### Pediatric Patients

##### Hypokalemia†

###### Prevention or Treatment†

Oral

3 mEq/kg daily for young children.

#### Adults

##### Hypokalemia

###### Prevention or Treatment

Oral

Usually should not exceed 200 mEq daily.

### Special Populations

#### Renal Impairment

Cautious dosage selection and careful monitoring recommended in patients with renal impairment.

#### Geriatric Patients

Select dosage with caution, starting at low end of dosage range, because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.

## Cautions for Potassium Supplements

### Contraindications

- Hyperkalemia, including that complicating chronic renal failure, systemic acidosis (e.g., diabetic acidosis), acute dehydration, extensive tissue breakdown (e.g., in severe burns), adrenal insufficiency, or concomitant use of potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene).

- Severe renal impairment with oliguria, anuria, or azotemia.

- Use of solid oral dosage preparations in patients with structural, pathologic (e.g., diabetic gastroparesis), and/or pharmacologic (e.g., induced by anticholinergic agents) causes for arrest or delay in GI transit.

- Use of extended-release preparations in patients with esophageal compression caused by an enlarged left atrium.

### Warnings/Precautions

#### Warnings

##### Hyperkalemia

Hyperkalemia and cardiac arrest can occur following use of potassium supplements in patients with impaired mechanisms for excreting potassium. Most common and serious adverse effect of potassium therapy.

Potentially fatal; can develop rapidly and patients may be asymptomatic. Occurs most frequently with IV potassium (especially if administered too rapidly), but may occur with oral potassium.

Use IV solutions containing potassium with extreme caution, if at all, in patients with hyperkalemia, severe renal failure, or other conditions with potassium retention.

Evaluate renal function before therapy; monitor clinical status with periodic ECGs and/or determinations of plasma potassium concentrations.

Clinical signs and symptoms of hyperkalemia include paresthesia of the extremities, listlessness, mental confusion, weakness or heaviness of the legs, flaccid paralysis, cold skin, gray pallor, peripheral vascular collapse with fall in blood pressure, cardiac arrhythmias, and heart block.

##### Metabolic Acidosis

In patients who have both hypokalemia and metabolic acidosis, an alkalinizing potassium salt (acetate, bicarbonate, citrate, gluconate) should be used for treatment of hypokalemia.

##### Fluid Overload and Edematous States

Use of IV solutions containing potassium may cause fluid and/or solute overload, leading to decreased electrolyte concentrations, overhydration, congestion, and pulmonary edema.

Use IV solutions containing potassium with extreme caution, if at all, in patients with CHF, severe renal insufficiency, or other conditions with sodium retention and edema.

##### GI Lesions

Solid oral dosage forms of potassium have resulted in ulcerative and/or stenotic GI lesion; perforation has occurred. Possibly more frequent with enteric-coated tablets (no longer commercially available in the US).

Administer wax matrix and extended-release preparations with caution; discontinue immediately if abdominal pain, distention, severe vomiting, or GI bleeding occurs.

Reserve use of extended-release potassium chloride preparations for patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for those in whom there is a problem of compliance with these latter dosage forms.

Some experts question the use of any solid potassium preparation, since use of dilute liquid preparations minimizes the risk of GI complications.

##### Local Reactions

Pain and phlebitis may occur at IV administration site, especially with potassium solutions containing ≥30 mEq/L.

#### General Precautions

##### Laboratory Monitoring

Monitor fluid balance, electrolyte concentrations, and acid-base balance periodically during therapy. Regular serum potassium determinations are recommended, especially in patients with renal impairment or diabetic nephropathy.

##### Use of Parenteral Solutions

When potassium is administered IV in parenteral solutions, consider the cautions, precautions, and contraindications associated with fluid volume and electrolytes contained in the IV infusion fluid.

#### Specific Populations

##### Pregnancy

Category C.

##### Lactation

Not known whether potassium is distributed into milk. Use with caution.

##### Pediatric Use

Safety and efficacy not established.

##### Geriatric Use

Response in patients ≥65 years of age does not appear to differ from that in younger adults; however, use with caution due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.

Monitor renal function.

##### Renal Impairment

Parenteral solutions containing potassium may cause sodium and/or potassium retention.

Use cautiously; monitor plasma potassium concentrations frequently.

### Common Adverse Effects

Hyperkalemia; GI effects (nausea, vomiting, diarrhea, flatulence, abdominal pain or discomfort); infusion site reactions.

## Interactions for Potassium Supplements

### Specific Drugs

Drug | Interaction | Comments
--- | --- | ---
ACE inhibitors (e.g., captopril, enalapril) | Increased risk of hyperkalemia | Use concomitantly only if monitored closely; monitor serum potassium frequently
Corticosteroids |  | Use caution when used concomitantly with parenteral solutions containing potassium
Corticotropin (ACTH) |  | Use caution when used concomitantly with parenteral solutions containing potassium
Diuretics, potassium-sparing (e.g. amiloride, spironolactone, triamterene) | Increased risk of severe hyperkalemia | Concomitant use contraindicated

## Potassium Supplements Pharmacokinetics

### Absorption

#### Bioavailability

Well absorbed following oral administration.

Following oral administration of extended-release formulations, potassium is released slowly; risk of high, localized concentrations is minimized.

##### Plasma Concentrations

Normal plasma potassium concentrations generally range from 3.5–5 mEq/L in healthy adults.

Plasma concentrations up to 7.7 mEq/L may be normal in neonates.

Plasma potassium concentrations are not necessarily indicative of cellular potassium concentrations; cellular deficits may occur without concomitant decreases in plasma potassium concentrations. Hypokalemia may occur without substantial depletion of cellular potassium.

Extracellular fluid pH changes produce reciprocal effects on plasma potassium concentrations; 0.1 unit increase in plasma pH produces a decrease of 0.6 mEq/L in plasma potassium concentration.

### Distribution

#### Extent

Enters extracellular fluid and actively transported into cells; intracellular concentration is up to 40 times extracellular concentration.

Intracellular movement augmented by dextrose, insulin, and oxygen.

Potassium concentrations in gastric and intestinal secretions are higher than plasma concentrations; diarrheal fluid may contain up to 60 mEq/L.

### Elimination

#### Elimination Route

Excreted principally in urine; small amounts may be excreted via the skin and intestinal tract.

Filtered by the glomeruli, reabsorbed in the proximal tubule, and secreted in the distal tubule, the site of sodium-potassium exchange.

Tubular secretion influenced by chloride ion concentration, hydrogen ion exchange, acid-base equilibrium, and adrenal hormones.

Healthy adults on potassium-free diets usually excrete 40–50 mEq of potassium daily.

#### Special Populations

Potassium excretion decreased in patients with renal impairment.

Surgery and/or tissue injury result in increased urinary excretion of potassium which may continue for several days.

Postoperative patients or patients under stress of disease with normal kidneys may excrete up to 80–90 mEq of potassium daily, even though they are not receiving any potassium.

## Stability

### Storage

#### Oral

##### Capsules and Tablets

Tight, light resistant containers at 15–30°C.

##### Powder for Solution

15–30°C.

##### Solution

15–30°C.

#### Parenteral

##### Injection for IV Infusion

25°C (may be exposed to 15–30°C).

##### Concentrate For IV Infusion

25°C (may be exposed to up to 40°C).

### Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

#### Parenteral

##### Drug Compatibility (Potassium Acetate)

Admixture CompatibilityHID
Compatible
Metoclopramide HCl

Y-site CompatibilityHID
Compatible
Ciprofloxacin

##### Solution Compatibility (Potassium Chloride)HID

Compatible
Dextrose–Ringer’s injection combinations
Dextrose–Ringer’s injection, lactated, combinations
Dextrose 5% in Ringer’s injection, lactated
Dextrose–saline combinations
Dextrose 5% in sodium chloride 0.9%
Dextrose 2.5, 5, 10, or 20% in water
Ionosol products
Ringer’s injection
Ringer’s injection, lactated
Sodium chloride 0.45 or 0.9%
Sodium lactate 1/6 M
Variable
Fat emulsion 10%, IV

##### Drug Compatibility (Potassium Chloride)

Admixture CompatibilityHID
Compatible
Amikacin sulfate
Aminophylline
Amiodarone HCl
Atracurium besylate
Calcium gluconate
Cefepime HCl
Ceftazidime
Chloramphenicol sodium succinate
Ciprofloxacin
Clindamycin phosphate
Cytarabine
Dimenhydrinate
Dopamine HCl
Enalaprilat
Erythromycin lactobionate
Fluconazole
Foscarnet sodium
Fosphenytoin sodium
Furosemide
Heparin sodium
Hydrocortisone sodium succinate
Hydromorphone HCl
Isoproterenol HCl
Lidocaine HCl
Magnesium sulfate
Methyldopate HCl
Metoclopramide HCl
Mitoxantrone HCl
Nafcillin sodium
Nicardipine HCl
Norepinephrine bitartrate
Oxacillin sodium
Penicillin G potassium
Phenylephrine HCl
Ranitidine HCl
Sodium bicarbonate
Vancomycin HCl
Verapamil HCl
Incompatible
Amphotericin B
Variable
Dobutamine HCl
Penicillin G sodium

Y-Site CompatibilityHID
Compatible
Acyclovir sodium
Allopurinol sodium
Amifostine
Aminophylline
Amiodarone HCl
Ampicillin sodium
Anidulafungin
Atropine sulfate
Aztreonam
Bivalirudin
Calcium gluconate
Caspofungin acetate
Ceftaroline fosamil
Chlorpromazine HCl
Ciprofloxacin
Cisatracurium besylate
Cladribine
Clonidine HCl
Cyanocobalamin
Dexamethasone sodium phosphate
Dexmedetomidine HCl
Digoxin
Diltiazem HCl
Diphenhydramine HCl
Dobutamine HCl
Docetaxel
Dopamine HCl
Doripenem
Doxorubicin HCl liposome injection
Droperidol
Edrophonium chloride
Enalaprilat
Epinephrine HCl
Ertapenem sodium
Esmolol HCl
Estrogens, conjugated
Ethacrynate sodium
Etoposide phosphate
Famotidine
Fenoldopam mesylate
Fentanyl citrate
Filgrastim
Fludarabine phosphate
Fluorouracil
Furosemide
Gallium nitrate
Gemcitabine HCl
Gentamicin sulfate
Granisetron HCl
Heparin sodium
Hetastarch in lactated electrolyte injection (Hextend)
Hydralazine HCl
Hydroxyethyl starch 130/0.4 in sodium chloride 0.9%
Idarubicin HCl
Indomethacin sodium trihydrate
Isoproterenol HCl
Labetalol HCl
Levofloxacin
Lidocaine HCl
Linezolid
Lorazepam
Magnesium sulfate
Melphalan HCl
Meperidine HCl
Meropenem
Micafungin sodium
Midazolam HCl
Milrinone lactate
Morphine sulfate
Neostigmine methylsulfate
Nicardipine HCl
Norepinephrine bitartrate
Ondansetron HCl
Oxacillin sodium
Oxaliplatin
Oxytocin
Paclitaxel
Palonosetron HCl
Pantoprazole sodium
Pemetrexed disodium
Penicillin G potassium
Pentazocine lactate
Phytonadione
Piperacillin sodium–tazobactam sodium
Procainamide HCl
Prochlorperazine edisylate
Propofol
Propranolol HCl
Quinupristin-dalfopristin
Remifentanil HCl
Sargramostim
Scopolamine HBr
Sodium bicarbonate
Sodium nitroprusside
Succinylcholine chloride
Tacrolimus
Telavancin HCl
Teniposide
Theophylline
Thiotepa
Tigecycline
Tirofiban HCl
Trimethobenzamide HCl
Vinorelbine tartrate
Warfarin sodium
Zidovudine
Incompatible
Amphotericin B cholesteryl sulfate complex
Azithromycin
Diazepam
Ergotamine tartrate
Phenytoin sodium
Variable
Aldesleukin
Methylprednisolone sodium succinate
Promethazine HCl

## Actions

- The major cation of intracellular fluid; essential for maintenance of acid-base balance, isotonicity, and electrodynamic cellular function.

- Important activator in many enzymatic reactions; essential for transmission of nerve impulses; contraction of cardiac, smooth, and skeletal muscles; gastric secretion; renal function; tissue synthesis; and carbohydrate metabolism.

- Reduces mean SBP and DBP.

## Advice to Patients

- Importance of advising patient to take oral supplement with meal and full glass of water.

- Importance of taking only as prescribed; do not increase dosage or duration of therapy unless otherwise instructed by a clinician.

- Importance of informing clinician of tarry stools or other GI symptoms.

- Importance of informing clinician of difficulty swallowing capsules or if capsules seem to become stuck in throat.

- Advise patient to swallow capsules and not crush, chew, or suck capsules.

- Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.

- Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.

- Importance of informing patients of other important precautionary information. (See Cautions.)

## Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Acetate
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Parenteral | For injection concentrate | 2 mEq of K+/mL and CH3COO-/mL* | Potassium Acetate Injection |
|  | 2 mEq of K+/mL and CH3COO-/mL pharmacy bulk package* | Potassium Acetate Injection |
|  |  | Potassium Acetate Injection MaxiVial | Abraxis
|  | 4 mEq of K+/mL and CH3COO-/mL* | Potassium Acetate Injection |

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Bicarbonate
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Oral | Tablets, for solution | 10 mEq of K+ | Effer-K | Nomax
|  | 20 mEq of K+ | Effer-K | Nomax
|  | 25 mEq of K+* | Klor-Con/EF | Upsher-Smith
|  |  | Potassium Bicarbonate Effervescent Tablets |

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Chloride
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Oral | Capsules, extended-release | 8 mEq of K+ and Cl− | Micro-K | Ther-Rx
|  | 10 mEq of K+ and Cl−* | Micro-K | Ther-Rx
|  |  | Potassium Chloride Extended-Release Capsules |
| For solution | 20 mEq of K+ and Cl− per packet* | K-Lor | Abbott
|  |  | Kay Ciel | Forest
|  |  | Klor-Con Powder | Upsher-Smith
|  | 25 mEq of K+ and Cl− per packet | Klor-Con/25 Powder | Upsher-Smith
| Solution | 6.7 mEq of K+/5 mL and Cl-/5 mL* | Kay Ciel | Forest
|  |  | Potassium Chloride Oral Solution |
|  |  | Potassium Chloride Oral Solution |
|  |  | Potassium Chloride Oral Solution () |
|  |  | Potassium Chloride Oral Solution () |
|  | 13.3 mEq of K+/5 mL and Cl-/5 mL* | Potassium Chloride Oral Solution () |
| Tablets, extended-release | 10 mEq of K+ and Cl− | Kaon-Cl-10 | Savage
| Tablets, extended-release (containing coated potassium chloride crystals) | 10 mEq of K+ and Cl−* | Klor-Con M10 | Upsher-Smith
|  |  | Potassium Chloride Extended-Release Tablets |
|  | 15 mEq of K+ and Cl− | Klor-Con M15 (scored) | Upsher-Smith
|  | 20 mEq of K+ and Cl−* | Klor-Con M20 (scored) | Upsher-Smith
|  |  | Potassium Chloride Extended-Release Tablets (scored) |
|  |  | Potassium Chloride Extended-Release Tablets (scored) |
| Tablets, extended-release, film-coated | 8 mEq of K+ and Cl−* | Klor-Con 8 | Upsher-Smith
|  |  | Potassium Chloride Extended-Release Tablets |
|  | 10 mEq of K+ and Cl−* | Klor-Con 10 | Upsher-Smith
|  |  | Klotrix | Bristol-Myers Squibb
|  |  | K-Tab Filmtab | Abbott
|  |  | Potassium Chloride Extended-Release Tablets |
Parenteral | For injection concentrate | 1.5 mEq of K+ and Cl− per mL* | Potassium Chloride for Injection Concentrate |
|  | 2 mEq of K+ and Cl− per mL* |  |
|  | 2 mEq of K+ and Cl− per mL pharmacy bulk package* | Potassium Chloride for Injection Concentrate | Hospira
| For injection concentrate, for IV infusion | 0.1 mEq of K+ and Cl− per mL (10 mEq)* | Potassium Chloride for Injection Concentrate |
|  |  | Potassium Chloride Injection Highly Concentrated (Viaflex) | Baxter
|  | 0.2 mEq of K+ and Cl− per mL (10 and 20 mEq)* | Potassium Chloride Injection Highly Concentrated (Viaflex) | Baxter
|  | 0.3 mEq of K+ and Cl− per mL (30 mEq)* | Potassium Chloride Injection Highly Concentrated (Viaflex) | Baxter
|  | 0.4 mEq of K+ and Cl− per mL (20 and 40 mEq)* | Potassium Chloride Injection Highly Concentrated (Viaflex) | Baxter

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Chloride in Dextrose Injection
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Parenteral | Injection, for IV infusion only | 10 mEq of K+ per L in 5% Dextrose* | 10 mEq/L Potassium Chloride in 5% Dextrose Injection (Viaflex) | Baxter
|  | 20 mEq of K+ per L in 5% Dextrose* | 20 mEq/L Potassium Chloride in 5% Dextrose Injection (Viaflex) | Baxter
|  |  | 20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose Injection | Braun, Hospira
|  | 30 mEq of K+ per L in 5% Dextrose* | 30 mEq/L Potassium Chloride in 5% Dextrose Injection (Viaflex) | Baxter
|  |  | 30 mEq/L (0.224%) Potassium Chloride in 5% Dextrose Injection | Hospira
|  | 40 mEq of K+ per L in 5% Dextrose* | 40 mEq/L Potassium Chloride in 5% Dextrose Injection (Viaflex) | Baxter
|  |  | 40 mEq (0.3%) Potassium Chloride in 5% Dextrose Injection |

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Chloride in Sodium Chloride Injection
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Parenteral | Injection, for IV infusion only | 20 mEq of K+ per L in 0.9% Sodium Chloride* | 20 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 20 mEq/L (0.15%) Potassium Chloride in 0.9% Sodium Chloride Injection |
|  | 40 mEq of K+ per L in 0.9% Sodium Chloride* | 40 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 40 mEq/L (0.3%) Potassium Chloride in 0.9% Sodium Chloride Injection |

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Chloride in Dextrose and Lactated Ringer’s Injection
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Parenteral | Injection, for IV infusion only | 20 mEq of K+ per L in 5% Dextrose and Lactated Ringer’s* | 20 mEq/L Potassium Chloride in 5% Dextrose and Lactated Ringer’s Injection (Viaflex) | Baxter
|  |  | 20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose and Lactated Ringer’s Injection |
|  | 40 mEq of K+ per L in 5% Dextrose and Lactated Ringer’s* | 40 mEq/L Potassium Chloride in 5% Dextrose and Lactated Ringer’s Injection (Viaflex) | Baxter
|  |  | 40 mEq/L (0.3%) Potassium Chloride in 5% Dextrose and Lactated Ringer’s Injection |

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Chloride in Dextrose and Sodium Chloride Injection
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Parenteral | Injection, for IV infusion only | 10 mEq of K+ per L in 5% Dextrose and 0.2–0.225% Sodium Chloride* | 10 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | (0.075%) 10 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection |
|  |  | 10 mEq/L (0.075%) Potassium Chloride in 5% Dextrose and 0.225% Sodium Chloride Injection |
|  | 10 mEq of K+ per L in 5% Dextrose and 0.3–0.33% Sodium Chloride* | 10 mEq/L (0.075%) Potassium Chloride in 5% Dextrose and 3% Sodium Chloride Injection |
|  |  | 10 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection (Viaflex) | Baxter
|  | 10 mEq of K+ per L in 5% Dextrose and 0.45% Sodium Chloride* | 10 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 10 mEq/L (0.075%) Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection |
|  | 20 mEq of K+ per L in 5% Dextrose and 0.2–0.225% Sodium Chloride* | 20 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose and 0.225% Sodium Chloride Injection |
|  |  | (0.15%) 20 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection |
|  | 20 mEq K+ per L in 5% Dextrose and 0.3–0.33% Sodium Chloride* | 20 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose and 0.3% Sodium Chloride Injection |
|  | 20 mEq of K+ per L in 5% Dextrose and 0.45% Sodium Chloride* | 20 mEq Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 20 mEq/L (0.15%) Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection |
|  | 20 mEq of K+ per L in 5% Dextrose and 0.9% Sodium Chloride* | 20 mEq/L Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 20 mEq (0.15%) Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection |
|  | 20 mEq of K+ per L in 10% Dextrose and 0.2% Sodium Chloride* | (0.15%) 20 mEq/L Potassium Chloride in 10% Dextrose and 0.2% Sodium Chloride Injection |
|  | 30 mEq of K+ per L in 5% Dextrose and 0.2–0.225% Sodium Chloride* | 30 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 30 mEq/L (0.224%) Potassium Chloride in 5% Dextrose and 0.225% Sodium Chloride Injection |
|  |  | (0.22%) 30 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection |
|  | 30 mEq of K+ per L in 5% Dextrose and 0.3–0.33% Sodium Chloride* | 30 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 30 mEq/L (0.224%) Potassium Chloride in 5% Dextrose and 0.3% Sodium Chloride Injection |
|  | 30 mEq of K+ per L in 5% Dextrose and 0.45% Sodium Chloride* | 30 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 30 mEq/L (0.224%) Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection |
|  |  | (0.22%) 30 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection |
|  | 40 mEq of K+ per L in 5% Dextrose and 0.2–0.225% Sodium Chloride* | 40 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 40 mEq/L (0.3%) Potassium Chloride in 5% Dextrose and 0.225% Sodium Chloride Injection |
|  |  | (0.3%) 40 mEq/L Potassium Chloride in 5% Dextrose and 0.2% Sodium Chloride Injection |
|  | 40 mEq of K+ per L in 5% Dextrose and 0.3–0.33% Sodium Chloride* | 40 mEq/L Potassium Chloride in 5% Dextrose and 0.33% Sodium Chloride Injection |
|  |  | 40 mEq/L (0.3%) Potassium Chloride in 5% Dextrose and 0.3% Sodium Chloride Injection |
|  | 40 mEq of K+ per L in 5% Dextrose and 0.45% Sodium Chloride* | 40 mEq/L Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection (Viaflex) | Baxter
|  |  | 40 mEq/L (0.3%) Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection |
|  | 40 mEq of K+ per L in 5% Dextrose and 0.9% Sodium Chloride* | 40 mEq/L Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection (Viaflex) | Baxter

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Chloride in Water
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Parenteral | Injection, for IV infusion only | 0.1 mEq per mL (10 mEq)* | Potassium Chloride in Water for Injection (Premixed) (LifeCare) | Hospira
|  | 0.2 mEq per mL (10 and 20 mEq)* | Potassium Chloride in Water for Injection (Premixed) (LifeCare) | Hospira
|  | 0.3 mEq per mL (30 mEq)* | Potassium Chloride in Water for Injection (Premixed) (LifeCare) | Hospira
|  | 0.4 mEq per mL (20 and 40 mEq)* | Potassium Chloride in Water for Injection (Premixed) (LifeCare) | Hospira

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Bicarbonate and Potassium Chloride
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Oral | Tablets, for solution | 25 mEq of K+ and Cl− (provided by potassium bicarbonate 0.5 g and potassium chloride 1.5 g)* | Potassium Effervescent Tablets |

AHFS DI Essentials™. © Copyright 2023, Selected Revisions March 25, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

Reload page with references included

Medical Disclaimer